Trial · NCT00723554
Registered outcomes44
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 44
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Reporting Treatment-emergent Adverse Events (AEs) | From the first dose to last dose of investigational product, an average of approximately 268 days, plus 48 hours | Number of patients reporting at least one treatment-emergent AE/Serious AE |
| Primary | Number of Patients Who Discontinued Iloprost PD-15 Treatment Due to an AE | From the first dose of investigational product to study discontinuation, an average of approximately 268 days | Number of patients reporting at least one treatment-emergent AE/Serious AE leading to discontinuation of study investigational treatment |
| Primary | Number of Patients Reporting Treatment-emergent Serious AEs | From the first to last dose of investigational product, an average of approximately 268 days, plus 48 hours | Number of patients reporting at least one treatment-emergent serious AEs |
| Primary | Systolic Blood Pressure - Iloprost PD-6 (Period 1) | Day 1 | Systolic blood pressure was measured immediately prior to first dosing with Iloprost PD-15 |
| Primary | Systolic Blood Pressure - Iloprost PD-15 (Period 2) | Day 28 | Systolic blood pressure was measured on Day 28 of treatment with Iloprost PD-15 |
| Primary | Systolic Blood Pressure - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Systolic blood pressure was measured at the end of study visit |
| Primary | Change in Systolic Blood Pressure - (Period 1 to Period 2) | Day 1 and Day 28 | Systolic blood pressure was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and Day 28 of treatment with Iloprost PD-15 (Period 2) |
| Primary | Change in Systolic Blood Pressure - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Systolic blood pressure was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and at the end of treatment with Iloprost PD-15 (Period 3) |
| Primary | Diastolic Blood Pressure - Iloprost PD-6 (Period 1) | Day 1 | Diastolic blood pressure was measured immediately prior to first dosing with Iloprost PD-15 |
| Primary | Diastolic Blood Pressure - Iloprost PD-15 (Period 2) | Day 28 | Diastolic blood pressure was measured on Day 28 of treatment with Iloprost PD-15 |
| Primary | Diastolic Blood Pressure - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Diastolic blood pressure was measured at the end of study visit |
| Primary | Change in Diastolic Blood Pressure - (Period 1 to Period 2) | Day 1 and Day 28 | Diastolic blood pressure was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and Day 28 of treatment with Iloprost PD-15 (Period 2) |
| Primary | Change in Diastolic Blood Pressure - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Diastolic blood pressure was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and at the end of treatment with Iloprost PD-15 (Period 3) |
| Primary | Heart Rate - Iloprost PD-6 (Period 1) | Day 1 | Heart rate was measured immediately prior to first dosing with Iloprost PD-15 |
| Primary | Heart Rate - Iloprost PD-15 (Period 2) | Day 28 | Heart rate was measured on Day 28 of treatment with Iloprost PD-15 |
| Primary | Heart Rate - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Heart rate was measured at the end of study visit |
| Primary | Change in Heart Rate - (Period 1 to Period 2) | Day 1 and Day 28 | Heart rate was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and Day 28 of treatment with Iloprost PD-15 (Period 2) |
| Primary | Change in Heart Rate - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Heart rate was measured on Day 1 prior to treatment with Iloprost PD-15 (Period 1) and at the end of treatment with Iloprost PD-15 (Period 3) |
| Secondary | Average Inhalation Time - Iloprost PD-6 (Period 1) | average of approximately 28 days | The time and date of inhalation, inhalation time (minutes), and dose completion status (\<12.5%, ≥12.5 to \<100%, full) were recorded in the memory chip of the I-neb® AAD® each time it was used. |
| Secondary | Average Inhalation Time - Iloprost PD-15 (Period 2) | average of approximately 28 days | The time and date of inhalation, inhalation time (minutes), and dose completion status (\<12.5%, ≥12.5 to \<100%, full) were recorded in the memory chip of the I-neb® AAD® each time it was used. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00723554/registered